Heartflow, Inc. (NASDAQ:HTFL) Receives $38.60 Average Price Target from Analysts

Heartflow, Inc. (NASDAQ:HTFL) has been assigned a consensus recommendation of “Hold” from the seven research firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $38.60.

A number of research firms have issued reports on HTFL. JPMorgan Chase & Co. lifted their target price on Heartflow from $36.00 to $40.00 and gave the company an “overweight” rating in a research report on Thursday, November 13th. Weiss Ratings initiated coverage on shares of Heartflow in a report on Saturday, November 1st. They set a “sell (d+)” rating on the stock. Zacks Research raised shares of Heartflow to a “hold” rating in a research note on Wednesday, September 3rd. Stifel Nicolaus boosted their target price on shares of Heartflow from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Finally, Wall Street Zen upgraded shares of Heartflow to a “hold” rating in a report on Saturday, August 16th.

Heartflow Price Performance

Shares of HTFL opened at $27.67 on Friday. The company’s 50 day moving average price is $34.06. Heartflow has a one year low of $25.75 and a one year high of $41.22.

Heartflow (NASDAQ:HTFL) last issued its quarterly earnings results on Friday, September 19th. The company reported ($1.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($1.26). The firm had revenue of $43.42 million during the quarter, compared to the consensus estimate of $43.20 million.

Institutional Trading of Heartflow

Hedge funds and other institutional investors have recently made changes to their positions in the company. TFC Financial Management Inc. bought a new position in Heartflow in the 3rd quarter valued at approximately $40,000. Emerald Mutual Fund Advisers Trust bought a new position in shares of Heartflow during the third quarter valued at $4,418,000. TrueMark Investments LLC acquired a new position in shares of Heartflow during the third quarter worth $918,000. Baillie Gifford & Co. bought a new stake in shares of Heartflow in the third quarter worth $101,182,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Heartflow in the third quarter valued at $234,000.

Heartflow Company Profile

We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of March 31, 2025, our Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone.